Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Cytokinetics Inc (CYTK)  
$62.72 0.52 (0.84%) as of 4:30 Fri 12/19


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 144,135,000
Market Cap: 9.04(B)
Last Volume: 8,264,325 Avg Vol: 8,203,231
52 Week Range: $29.84 - $68.15
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  1083
Guru Rank Value     : 0
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Cytokinetics is a biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. Co.'s clinical-stage drug candidates are: Omecamtiv mecarbil, which is being evaluated for the potential treatment of heart failure; Reldesemtiv, which is being evaluated for treatment in patients with amyotrophic lateral sclerosis; Aficamten, which is an oral, small molecule cardiac myosin inhibitor being evaluated in patients with symptomatic, obstructive hypertrophic cardiomyopathy; and CK-3772271, its second cardiac myosin inhibitor.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 98,008 146,914 414,419 908,352
Total Sell Value $6,125,326 $8,187,607 $19,218,950 $50,303,323
Total People Sold 8 8 10 11
Total Sell Transactions 19 32 72 126
End Date 2025-09-21 2025-06-20 2024-12-20 2023-12-21

   
Records found: 949
  Page 1 of 38  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Malik Fady Ibraham EVP Research & Development   •       •      –    2025-12-16 4 S $61.24 $134,728 D/D (2,200) 138,552 -0%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2025-12-16 4 OE $10.60 $23,320 D/D 2,200 140,752     -
   Callos Andrew EVP, Chief Commercial Officer   •       •      –    2025-12-08 4 S $65.96 $68,730 D/D (1,042) 50,660 3%     
   Callos Andrew EVP, Chief Commercial Officer   •       •      –    2025-12-08 4 OE $39.13 $40,773 D/D 1,042 51,702     -
   Malik Fady Ibraham EVP Research & Development   •       •      –    2025-12-02 4 S $63.89 $140,558 D/D (2,200) 140,610 2%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2025-12-02 4 OE $10.60 $23,320 D/D 2,200 142,810     -
   Henderson John T Director   •       •      –    2025-12-02 4 S $63.90 $559,125 D/D (8,750) 74,578 2%     
   Henderson John T Director   •       •      –    2025-12-02 4 OE $10.00 $87,500 D/D 8,750 83,328     -
   Harrington Robert Arthur Director   •       •      –    2025-12-01 4 S $66.80 $143,620 D/D (2,150) 18,542 6%     
   Kaye Edward M. Md Director   •       •      –    2025-12-01 4 S $66.72 $1,872,430 D/D (28,064) 9,977 6%     
   Kaye Edward M. Md Director   •       •      –    2025-12-01 4 OE $12.40 $384,994 D/D 28,064 38,041     -
   Parshall B Lynne Director   •       •      –    2025-11-19 4 S $64.73 $323,650 D/D (5,000) 22,933 4%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2025-11-18 4 S $66.45 $146,190 D/D (2,200) 140,610 6%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2025-11-18 4 OE $10.60 $23,320 D/D 2,200 142,810     -
   Hessekiel Jeffrey Chief Legal & Admin Officer   •       •      –    2025-11-14 4 A $0.00 $0 D/D 87,297 87,297     -
   Kaye Edward M. Md Director   •       •      –    2025-11-11 4 S $65.08 $336,789 D/D (5,175) 9,977 6%     
   Kaye Edward M. Md Director   •       •      –    2025-11-11 4 OE $9.66 $49,991 D/D 5,175 15,152     -
   Blum Robert I President & CEO   •       •      –    2025-11-05 4 GD $0.00 $0 D/D 2,000 356,108     -
   Malik Fady Ibraham EVP Research & Development   •       •      –    2025-11-04 4 S $59.55 $136,667 D/D (2,295) 140,610 -4%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2025-11-04 4 OE $10.60 $24,327 D/D 2,295 142,905     -
   Blum Robert I President & CEO   •       •      –    2025-10-30 4 S $62.86 $314,300 D/D (5,000) 358,108 0%     
   Wierenga Wendell Director   •       •      –    2025-10-27 4 S $58.68 $256,725 D/D (4,375) 32,444 -3%     
   Wierenga Wendell Director   •       •      –    2025-10-27 4 OE $10.00 $43,750 D/D 4,375 36,819     -
   Malik Fady Ibraham EVP Research & Development   •       •      –    2025-10-21 4 S $58.22 $122,553 D/D (2,105) 140,610 -8%     
   Malik Fady Ibraham EVP Research & Development   •       •      –    2025-10-21 4 OE $10.60 $22,313 D/D 2,105 142,715     -
  949 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 38
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2025 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us